Обзорен преглед на концепцията за здравословно затлъстяване

Neeland IJ, Poirier P, Després J-P. Cardiovascular and metabolic heterogeneity of obesity. Circulation. 2018, 137(13):1391-1406.

Ng M, Fleming T, Robinson M et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2014, 384(9945):766-781.

Collaborators GBDO, Afshin A, Forouzanfar MH, Reitsma M еt al.Health effects of overweight and obesity in 195 countries over 25 years. N. Engl. J. Med., 2017, 377(1): 13-27.

Beyene HB, Giles C, Huynh K еt al. Metabolic phenotyping of BMI to characterize cardiometabolic risk: evidence from large population-based cohorts Nat Commun, 2023, 14(6280):1-19.

World Health Organization Obesity and Overweight. (accessed on 19 April 2021). Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

Romieu I, Dossus L, Barquera S et al. Energy balance and obesity: what are the main drivers? Cancer Causes Control. 2017, 28(3):247-258.

Gray CL, Messer LC, Rappazzo KM et al. The association between physical inactivity and obesity is modified by five domains of environmental quality in U.S. adults: A cross-sectional study. PLOS ONE, 2018, 13(8):e0203301.

Oguoma VM, Coffee NT, Alsharrah S et al. Prevalence of overweight and obesity, and associations with socio-demographic factors in Kuwait. BMC Public Health. 2021, 21(1):667-680.

Choquet H, Meyre D. Genetics of obesity: What have we learned? Curr. Genomics, 2011, 12(3):169-179.

Kakoly NS, Earnest A, Teede HJ et al. The impact of obesity on the incidence of type 2 diabetes among women with polycystic ovary syndrome. Diabetes Care, 2019, 42(4):560-567.

Toplak H, et al. “Diabesity”-Obesity and type 2 diabetes (Update 2019). Wien Klin Wochenschr. 2019;131:71-76.

Cercato C, Fonseca FA. Cardiovascular risk and obesity. Diabetol. Metab. Syndr. 2019, 11(74):1-15.

Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell, 2014,156 (1-2): 20–44.

Manolopoulos KN, Karpe F, Frayn KN. Gluteofemoral body fat as a determinant of metabolic health. Int J Obes (Lond), 2010, 34(6):949-959.

Chait A, den Hartigh LJ. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med, 2020, 7(22):1-41.

Kim SK, Kim HJ, Hur KY et al. Visceral fat thickness measured by ultrasonography can estimate not only visceral obesity but also risks of cardiovascular and metabolic diseases. Am J Clin Nutr, 2004,79(4):593-599.

Van der Poorten D, Milner KL, Hui J et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology, 2008, 48(2):449-457.

Item F, Konrad D. Visceral fat and metabolic inflammation: the portal theory revisited. Obes Rev, 2012, 13(Suppl 2):30-39.

Fontana L, Eagon JC, Trujillo ME et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes, 2007, 56(4):1010-1013.

An SM, Cho SH, Yoon JC. Adipose Tissue and Metabolic Health.Diab Metab J, 2023, 47(5):595-611.

Harvey I, Boudreau A, Stephens JM. Adipose tissue in health and disease. Open Biol. 2020, 10(12):1-12.

Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol Aspects Med. 2013, 34(1):1-11.

Eder K, Baffy N, Falus A, Fulop AK. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res, 2009, 58(11):727-736.

Ortega FB, Sui X, Lavie CJ, Blair SN. Body mass index, the most widely used but also widely criticized index: would a criterion standard measure of total body fat be a better predictor of cardiovascular disease mortality? Mayo Clin Proc, 2016, 91(4):443-455.

Piché M-E, Tchernof A, Després J-P. Obesity phenotypes, diabetes, and cardiovascular diseases. Circulation Res, 2020, 126(11):1477-1500.

Linge J, Whitcher B, Borga M et al. Sub-phenotyping metabolic disorders using body composition: an individualized, nonparametric approach utilizing large data sets. Obesity, 2019, 27(7):1190-1199.

Ganz ML, Wintfeld N, Li Q et al. The association of body mass index with the risk of type 2 diabetes: a case–control study nested in an electronic health records system in the United States. Diabetol. Metab. Syndr. 2014, 6(1):50.

Gupta S, Bansal S. Does a rise in BMI cause an increased risk of diabetes?: Evidence from India. PLOS ONE, 2020, 15(4):1-20.

Zhu X, Hu J, Guo H et al. Effect of metabolic health and obesity phenotype on risk of diabetes mellitus: A population-based longitudinal study. Diabetes Metab Syndr Obes, 2021, 14:3485-3498.

Lin Z, Feng W, Liu Y et al. Machine learning to identify metabolic subtypes of obesity: A multi-center study. Front. Endocrinol, 2021, 12: 1-12.

Martin S, Cule M, Basty N et al. Genetic evidence for different adiposity phenotypes and their opposing influences on ectopic fat and risk of cardiometabolic disease. Diabetes, 2021, 70(8):1843-1856.

Gujral UP, Mohan V, Pradeepa R et al. Ethnic differences in the prevalence of diabetes in underweight and normal weight individuals: The CARRS and NHANES studies. Diabetes Res, Clin Pract, 2018, 146:34-40.

Tchernof A, Després J-P. Pathophysiology of human visceral obesity: An update. Physiological Rev, 2013, 93(1):359-404.

Gonzalez-Muniesa P, Mártinez-González MA, Hu F B et al. Obesity. Nat Rev Dis Prim, 2017;3:17034.

Zhang J, Jiang H, Chen J. Combined effect of body mass index and metabolic status on the risk of prevalent and incident chronic kidney disease: a systematic review and meta-analysis. Oncotarget, 2017, 8(22):35619-35629.

Stefan N, Haring HU, Hu FB, Schulze MB. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol, 2013, 1(2):152-162.-

Caleyachetty R, Thomas GN, Toulis KA et al. Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. J Am Coll Cardiol, 2017, 70(12):1429-1437.

April-Sanders AK, Rodriguez CJ. Metabolically healthy obesity redefined. JAMA Netw. Open. 2021;4(5):e218860.

Mathew H, Farr OM, Mantzoros CS. Metabolic health and weight: Understanding metabolically unhealthy normal weight or metabolically healthy obese patients. Metab Clin Exp, 2016, 65(1):73-80.

Oguoma, V. M. Abu-Farha M, Coffee NT et al. Metabolically healthy and unhealthy obese phenotypes among arabs and south asians: prevalence and relationship with cardiometabolic indicators. Nutrients, 2022,14(5):915.

Gao M, Lv J, Yu C et al. Metabolically healthy obesity, transition to unhealthy metabolic status, and vascular disease in Chinese adults: A cohort study. PLOS Med. 2020;17(10):e1003351.

Wildman RP, Muntner P, Reynolds K et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med, 2008, 168(15):1617-1624.

Zheng Q, Lin W, Liu C et al. Prevalence and epidemiological determinants of metabolically obese but normal-weight in Chinese population. BMC Public Health, 2020, 20(1):487-497.

Schulze MB. Metabolic health in normal-weight and obese individuals. Diabetologia, 2019, 62(4):558-566.

Cirulli ET, Guo L, Swisher CL et al. Profound perturbation of the metabolome in obesity Is associated with health risk. Cell Metab. 2019, 29(2):488-500.

Ottosson F, Smith E, Ericson U et al. Metabolome-defined obesity and the risk of future diabetes and mortality. Diabetes Care, 2022, 45(5):1260-1267.

Stefan N, Schick F, Häring HU. Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metab. 2017, 26(2):292-300.

Stefan N, Häring HU, Schulze MB. Metabolically healthy obesity: the low-hanging fruit in obesity treatment? Lancet Diabetes Endocrinol. 2018, 6(3):249-258.

Blüher M. Are metabolically healthy obese individuals really healthy? Eur J Endocrinol. 2014, 171(6):209-219.

Blüher M. The distinction of metabolically “healthy” from “unhealthy” obese individuals. Curr Opin Lipidol., 2010, 21(1):38-43.

Eckel N, Li Y, Kuxhaus O et al. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses’ Health Study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol., 2018, 6(9):714-724.

Blüher M. Metabolically Healthy Obesity. Endocr Rev, 2020, 41(3), 170-177.

Eckel N, Meidtner K, Kalle-Uhlmann T et al. Metabolically healthy obesity and cardiovascular events: a systematic review and metaanalysis. Eur J Prev Cardiol, 2016, 23(9):956-966.

Magkos F. Metabolically healthy obesity: what’s in a name? Am J Clin Nutr., 2019,110(3),533-539.

Lavie CJ, Laddu D, Arena R et al. Healthy weight and obesity prevention: JACC health promotion series. J Am Coll Cardiol., 2018, 72(13):1506-1531.

Chait A, den Hartigh LJ. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med 2020,7:22.

Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest, 2019,129(10):3978-3989.

Kouvari M, Panagiotakos DB, Yannakoulia M et al. Transition from metabolically benign to metabolically unhealthy obesity and 10-year cardiovascular disease incidence: the ATTICA cohort study. Metabolism. 2019, 93:18-24.

Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008;134(5):1369-1375.

Allister CA, Liu LF, Lamendola CA et al. In vivo 2H2O administration reveals impaired triglyceride storage in adipose tissue of insulin-resistant humans. J Lipid Res, 2015,56(2):435-439.

Stefan N, Kantartzis K, Machann J et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med., 2008,168(15):1609-1616.

Blüher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes, 2009, 117(6):241-250.

Ghaben AL, Scherer PE. Adipogenesis and metabolic health. Nat Rev Mol Cell Biol. 2019, 20(4):242-258.

Mongraw-Chaffin M, Foster MC, Anderson CAM et al. Metabolically healthy obesity, transition to metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2018, 71(17):1857-1865.

Lin H, Zhang L, Zheng R, Zheng Y. The prevalence, metabolic risk, and effects of lifestyle intervention for metabolically healthy obesity: a systematic review and meta-analysis: A PRISMA-compliant article. Medicine (Baltimore). 2017, 96(47):e8838

Kabat GC, Wu WY, Bea JW et al. Metabolic phenotypes of obesity: frequency, correlates and change over time in a cohort of postmenopausal women. Int J Obes (Lond). 2017, 41(1):170-177

Appleton SL, Seaborn CJ, Visvanathan R et al. North West Adelaide Health Study Team. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care. 2013, 36(8):2388-2394.

Nilsson PM, Korduner J, Magnusson M. Metabolically Healthy Obesity (MHO) – New Research Directions for Personalised Medicine in Cardiovascular Prevention. Curr Hypertens Rep 2020, 22(2):18